An Appeal to the Global Health Community for a Tripartite Innovation: An "Essential Diagnostics List," "Health in All Policies," and "See-Through 21(st) Century Science and Ethics".
July 17, 2015 Editor 0
An Appeal to the Global Health Community for a Tripartite Innovation: An “Essential Diagnostics List,” “Health in All Policies,” and “See-Through 21(st) Century Science and Ethics”.
OMICS. 2015 Jul 10;
Authors: Dove ES, Barlas IÖ, Birch K, Boehme C, Borda-Rodriguez A, Byne WM, Chaverneff F, Coşkun Y, Dahl ML, Dereli T, Diwakar S, Elbeyli L, Endrenyi L, Eroğlu-Kesim B, Ferguson LR, Güngör K, Gürsoy U, Hekim N, Huzair F, Kaushik K, Kickbusch I, Kıroğlu O, Kolker E, Könönen E, Lin B, Llerena A, Malhan F, Nair B, Patrinos GP, Şardaş S, Sert Ö, Srivastava S, Steuten LM, Toraman C, Vayena E, Wang W, Warnich L, Özdemir V
Diagnostics spanning a wide range of new biotechnologies, including proteomics, metabolomics, and nanotechnology, are emerging as companion tests to innovative medicines. In this Opinion, we present the rationale for promulgating an “Essential Diagnostics List.” Additionally, we explain the ways in which adopting a vision for “Health in All Policies” could link essential diagnostics with robust and timely societal outcomes such as sustainable development, human rights, gender parity, and alleviation of poverty. We do so in three ways. First, we propose the need for a new, “see through” taxonomy for knowledge-based innovation as we transition from the material industries (e.g., textiles, plastic, cement, glass) dominant in the 20(th) century to the anticipated knowledge industry of the 21st century. If knowledge is the currency of the present century, then it is sensible to adopt an approach that thoroughly examines scientific knowledge, starting with the production aims, methods, quality, distribution, access, and the ends it purports to serve. Second, we explain that this knowledge trajectory focus on innovation is crucial and applicable across all sectors, including public, private, or public-private partnerships, as it underscores the fact that scientific knowledge is a co-product of technology, human values, and social systems. By making the value systems embedded in scientific design and knowledge co-production transparent, we all stand to benefit from sustainable and transparent science. Third, we appeal to the global health community to consider the necessary qualities of good governance for 21st century organizations that will embark on developing essential diagnostics. These have importance not only for science and knowledge-based innovation, but also for the ways in which we can build open, healthy, and peaceful civil societies today and for future generations.
PMID: 26161545 [PubMed – as supplied by publisher]
- Translating biotechnology to knowledge-based innovation, peace, and development? Deploy a Science Peace Corps–an open letter to world leaders.
- Insights into the Affordable Medicines Facility-malaria in Ghana: the role of caregivers and licensed chemical sellers in four regions.
- Good laboratory practices guarantee biosafety in the Sierra Leone-China friendship biosafety laboratory.
- The plasticity of NBS resistance genes in sorghum is driven by multiple evolutionary processes.
- Developing Biosensors in Developing Countries: South Africa as a Case Study.
- New study highlights effectiveness of a herpesvirus CMV-based vaccine against Ebola
Tags: Tripartite Innovation
Subscribe to our stories
- Giving Francophone African incubators the keys to accelerate growth entrepreneurship February 13, 2018
- Is acceleration the panacea for scaling growth entrepreneurs? Reflections from XL Africa February 13, 2018
- Why providing pre-seed and seed capital is the essential step to bringing West Africa and Sahel’s entrepreneurs to the next level February 13, 2018
- Global Investment Competitiveness: New Insights on FDI February 2, 2018
- BioInnovate Africa phase II launched February 2, 2018